OGD2 Pharma and Syndivia launch collaboration to develop an ADC targeting the O-acetyl-GD2 cancer antigen NANTES, France, Sept. 6, 2016 (GLOBE NEWSWIRE) -- OGD2 Pharma SAS, a biotechnology company developing innovative anti-cancer therapies targeting the O-acetylated form of the GD2 ganglioside...

OGD2 Pharma and Green Cross LabCell start collaboration for developing NK-cell therapeutics targeting the O-acetyl-GD2 cancer antigen Nantes, France and Seoul, Korea, June 21, 2016 (GLOBE NEWSWIRE) -- OGD2 Pharma SAS, a biotechnology company developing innovative anti-cancer therapies targeting the O-acetylated form of the GD2...